Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Abstract 1: Biomarkers of response and acquired resistance to TIL-ACT in solid tumors

Welles Robinson, Andrea Castro, Maise Al-Bakir, Jared J. Gartner, Christopher Aled Chamberlain, Anders H. Kverneland, Troels H. Borch, Inge Marie Svane, Marco Donia, Paul Robbins, Kevin Litchfield

Cancer Res (2024) 84 (6_Supplement): 1.

https://doi.org/10.1158/1538-7445.AM2024-1

Published: 22 March 2024

View articletitled, Abstract 1: Biomarkers of response and acquired resistance to TIL-ACT in solid tumors

Journal Articles

Abstract 5198: Non-invasive biomarkers of ECM turnover are prognostic for combinations of checkpoint inhibition immunotherapy in solid tumors

Caroline N. Bistrup, Vinicius Araujo Barbosa de Lima, Christina Jensen, Morten A. Karsdal, Inge Marie Svane, Ulrik Lassen, Nicholas Willumsen

Cancer Res (2024) 84 (6_Supplement): 5198.

https://doi.org/10.1158/1538-7445.AM2024-5198

Published: 22 March 2024

View articletitled, Abstract 5198: Non-invasive biomarkers of ECM turnover are prognostic for combinations of checkpoint inhibition immunotherapy in solid tumors

Journal Articles

Abstract 5153: The role of CCL22-specific CD4 T cells in modulating the immunosuppressive tumor microenvironment in ovarian cancer

Ines Lecoq, Evelina Martinenaite, Marie C. Westergaard, Inge Marie Svane, Mads H. Andersen

Cancer Res (2023) 83 (7_Supplement): 5153.

https://doi.org/10.1158/1538-7445.AM2023-5153

Published: 04 April 2023

View articletitled, Abstract 5153: The role of CCL22-specific CD4 T cells in modulating the immunosuppressive tumor microenvironment in ovarian cancer

Journal Articles

Abstract CT535: High clinical efficacy in poor prognosis patients with metastatic melanoma treated with an IDO/PD-L1 peptide vaccine in combination with nivolumab

Julie W. Kjeldsen, Cathrine L. Lorentzen, Evelina Martinenaite, Eva Ellebaek, Marco Donia, Eva Ehrnrooth, Mads H. Andersen, Inge Marie Svane

Cancer Res (2022) 82 (12_Supplement): CT535.

https://doi.org/10.1158/1538-7445.AM2022-CT535

Published: 15 June 2022

View articletitled, Abstract CT535: High clinical efficacy in poor prognosis patients with metastatic melanoma treated with an IDO/PD-L1 peptide vaccine in combination with nivolumab

Journal Articles

Abstract 388: Non-invasive biomarker potential of the fibroblast-derived collagen type III and collagen type XI for predicting outcome in metastatic melanoma patients treated with anti-PD-1 therapy

Christina Jensen, Anders Kverneland, Marco Donia, Neel I. Nissen, Morten A. Karsdal, Inge Marie Svane, Nicholas Willumsen

Cancer Res (2021) 81 (13_Supplement): 388.

https://doi.org/10.1158/1538-7445.AM2021-388

Published: 01 July 2021

View articletitled, Abstract 388: Non-invasive biomarker potential of the fibroblast-derived collagen type III and collagen type XI for predicting outcome in metastatic melanoma patients treated with anti-PD-1 therapy

Journal Articles

Abstract 386: Evaluation of CPa9-HNE - a peripheral biomarker based on neutrophil extracellular traps (NETs) - for predicting outcome in patients with metastatic melanoma treated with anti-PD-1 therapy

Christina Jensen, Anders Kverneland, Marco Donia, Joachim H. Mortensen, Morten A. Karsdal, Inge Marie Svane, Nicholas Willumsen

Cancer Res (2021) 81 (13_Supplement): 386.

https://doi.org/10.1158/1538-7445.AM2021-386

Published: 01 July 2021

View articletitled, Abstract 386: Evaluation of CPa9-HNE - a peripheral biomarker based on neutrophil extracellular traps (NETs) - for predicting outcome in patients with metastatic melanoma treated with anti-PD-1 therapy

Journal Articles

Abstract 3091: Liquid biopsy reflecting a T-cell permissive tumor microenvironment identifies metastatic melanoma patients responding to immune checkpoint inhibitor therapy

Christina Jensen, Dovile Sinkeviciute, Daniel H. Madsen, Patrik Önnerfjord, Morten Hansen, Henrik Schmidt, Inge Marie Svane, Morten A. Karsdal, Nicholas Willumsen

Cancer Res (2020) 80 (16_Supplement): 3091.

https://doi.org/10.1158/1538-7445.AM2020-3091

Published: 15 August 2020

View articletitled, Abstract 3091: Liquid biopsy reflecting a T-cell permissive tumor microenvironment identifies metastatic melanoma patients responding to immune checkpoint inhibitor therapy

Journal Articles

Abstract 2810: Exploring T cell- repertoire in the tumor microenvironment during check-point inhibition in patients with metastatic solid tumors

Vinicius Araujo Barbosa de Lima, Morten Hansen, Kristoffer Staal Rohrberg, Iben Spangaard, Inge Marie Svane, Ulrik Lassen

Cancer Res (2019) 79 (13_Supplement): 2810.

https://doi.org/10.1158/1538-7445.AM2019-2810

Published: 01 July 2019

View articletitled, Abstract 2810: Exploring T cell- repertoire in the tumor microenvironment during check-point inhibition in patients with metastatic solid tumors

Journal Articles

Abstract 3185: CAR-T cells can eradicate human uveal melanoma and immune-therapy resistant malignant melanoma in IL-2 transgenic NOD/SCID IL2 receptor gamma knockout mice

Elin Forsberg, Mattias Lindberg, Henrik Jespersen, Samuel Alsén, Roger Olofsson Bagge, Marco Donia, Inge Marie Svane, Ola Nilsson, Lars Ny, Lisa Nilsson, Jonas Nilsson

Cancer Res (2019) 79 (13_Supplement): 3185.

https://doi.org/10.1158/1538-7445.AM2019-3185

Published: 01 July 2019

View articletitled, Abstract 3185: CAR-T cells can eradicate human uveal melanoma and immune-therapy resistant malignant melanoma in IL-2 transgenic NOD/SCID IL2 receptor gamma knockout mice

Journal Articles

HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy–Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice

Elin M.V. Forsberg, Mattias F. Lindberg, Henrik Jespersen, Samuel Alsén, Roger Olofsson Bagge, Marco Donia, Inge Marie Svane, Ola Nilsson, Lars Ny, Lisa M. Nilsson, Jonas A. Nilsson

Cancer Res (2019) 79 (5): 899–904.

https://doi.org/10.1158/0008-5472.CAN-18-3158

Published: 01 March 2019

View articletitled, HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy–Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice

Includes: Supplementary data

Journal Articles

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

Cancer Res (2017) 77 (17): 4562–4566.

https://doi.org/10.1158/0008-5472.CAN-16-3172

Published: 31 August 2017

View articletitled, Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

Includes: Supplementary data

Journal Articles

Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4⁺ T- Cells, Which Dampen CD8⁺ T-cell Antitumor Reactivity

Marco Donia, Rikke Andersen, Julie W. Kjeldsen, Paolo Fagone, Shamaila Munir, Ferdinando Nicoletti, Mads Hald Andersen, Per thor Straten, Inge Marie Svane

Cancer Res (2015) 75 (18): 3747–3759.

https://doi.org/10.1158/0008-5472.CAN-14-2956

Published: 14 September 2015

View articletitled, Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity

Includes: Supplementary data

Journal Articles

Abstract 4303: Programmed death ligand 1 (PD-L1) expression in paired melanoma tumor samples

Torben Steiniche, Allan Vestergaard Danielsen, Zhen (Adelle) Wang, Patricia Switten Nielsen, Lars Bastholt, Henrik Schmidt, Inge Marie Svane, Marisa Dolled-Filhart, Kenneth Emancipator, Dianna Y. Wu, Michael Busch-Sorensen, Wei Zhou

Cancer Res (2015) 75 (15_Supplement): 4303.

https://doi.org/10.1158/1538-7445.AM2015-4303

Published: 01 August 2015

View articletitled, Abstract 4303: Programmed death ligand 1 (PD-L1) expression in paired melanoma tumor samples

Journal Articles

HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients

Shamaila Munir, Gitte Holmen Andersen, Özcan Met, Marco Donia, Thomas Mørch Frøsig, Stine Kiaer Larsen, Tobias Wirenfeldt Klausen, Inge Marie Svane, Mads Hald Andersen

Cancer Res (2013) 73 (6): 1764–1776.

https://doi.org/10.1158/0008-5472.CAN-12-3507

Published: 14 March 2013

View articletitled, HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients

Includes: Supplementary data

Journal Articles

Dissection of T-cell Antigen Specificity in Human Melanoma

Rikke Sick Andersen, Charlotte Albæk Thrue, Niels Junker, Rikke Lyngaa, Marco Donia, Eva Ellebæk, Inge Marie Svane, Ton N. Schumacher, Per thor Straten, Sine Reker Hadrup

Cancer Res (2012) 72 (7): 1642–1650.

https://doi.org/10.1158/0008-5472.CAN-11-2614

Published: 01 April 2012

View articletitled, Dissection of T-cell Antigen Specificity in Human Melanoma

Includes: Supplementary data

Journal Articles

Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2

Rikke Bæk Sørensen, Tania Køllgaard, Rikke Sick Andersen, Joost Huibert van den Berg, Inge Marie Svane, Per thor Straten, Mads Hald Andersen

Cancer Res (2011) 71 (6): 2038–2044.

https://doi.org/10.1158/0008-5472.CAN-10-3403

Published: 14 March 2011

View articletitled, Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 1: Biomarkers of response and acquired resistance to TIL-ACT in solid tumors

Abstract 5198: Non-invasive biomarkers of ECM turnover are prognostic for combinations of checkpoint inhibition immunotherapy in solid tumors

Abstract 5153: The role of CCL22-specific CD4 T cells in modulating the immunosuppressive tumor microenvironment in ovarian cancer

Abstract CT535: High clinical efficacy in poor prognosis patients with metastatic melanoma treated with an IDO/PD-L1 peptide vaccine in combination with nivolumab

Abstract 388: Non-invasive biomarker potential of the fibroblast-derived collagen type III and collagen type XI for predicting outcome in metastatic melanoma patients treated with anti-PD-1 therapy

Abstract 386: Evaluation of CPa9-HNE - a peripheral biomarker based on neutrophil extracellular traps (NETs) - for predicting outcome in patients with metastatic melanoma treated with anti-PD-1 therapy

Abstract 3091: Liquid biopsy reflecting a T-cell permissive tumor microenvironment identifies metastatic melanoma patients responding to immune checkpoint inhibitor therapy

Abstract 2810: Exploring T cell- repertoire in the tumor microenvironment during check-point inhibition in patients with metastatic solid tumors

Abstract 3185: CAR-T cells can eradicate human uveal melanoma and immune-therapy resistant malignant melanoma in IL-2 transgenic NOD/SCID IL2 receptor gamma knockout mice

HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy–Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4⁺ T- Cells, Which Dampen CD8⁺ T-cell Antitumor Reactivity

Abstract 4303: Programmed death ligand 1 (PD-L1) expression in paired melanoma tumor samples

HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients

Dissection of T-cell Antigen Specificity in Human Melanoma

Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only